# Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer

> **NCT00429858** · PHASE2 · TERMINATED · sponsor: **Andrew Ko** · enrollment: 21 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** S-1
- **DRUG:** gemcitabine hydrochloride

## Key facts

- **NCT ID:** NCT00429858
- **Lead sponsor:** Andrew Ko
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-01-22
- **Primary completion:** 2010-01-20
- **Final completion:** 2010-01-20
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Study accrual rate is very slow, it was mandated by NCI to be terminated.
- **Last updated:** 2020-09-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00429858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00429858, "Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00429858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*